公开(公告)号：US20180344829A1

公开(公告)日：2018-12-06

申请号：US15776452

申请日：2016-11-17

Applicant: INNATE PHARMA

Inventor： STEPHANIE CORNEN ,  LAURENT GAUTHIER ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: A61K39/00 ,  C07K14/705 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/2803 ,  C07K14/705 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2319/30

Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

公开(公告)号：US20170369573A1

公开(公告)日：2017-12-28

申请号：US15541025

申请日：2016-01-04

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER

IPC: C07K16/28 ,  G06K9/62 ,  G06T7/11 ,  G06T7/00 ,  G06T11/00 ,  C07K16/46 ,  G06K9/66

CPC classification number: C07K16/2803 ,  A61B6/032 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/92 ,  G06K9/4604 ,  G06K9/6267 ,  G06K9/66 ,  G06T7/0012 ,  G06T7/11 ,  G06T11/003 ,  G06T2207/10081 ,  G06T2207/30024 ,  G06T2207/30061 ,  G06T2207/30096

Abstract: Monomeric Fc-domains are provided, as well as multimeric and single chain proteins comprising the monomeric Fc-domains. The proteins have utility in the treatment of disease. Included, inter glia, are multi specific polypeptides.

公开(公告)号：US20170267764A1

公开(公告)日：2017-09-21

申请号：US15458123

申请日：2017-03-14

Applicant: INNATE PHARMA

Inventor： MATHIEU BLERY ,  LAURENT GAUTHIER

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2833 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57492 ,  G01N2333/70539

Abstract: The present invention provides antigen-binding proteins capable of binding to human MICA polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by MICA-expressing cells, particularly cancer.

公开(公告)号：US20170158763A1

公开(公告)日：2017-06-08

申请号：US15125216

申请日：2015-03-12

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  NICOLAS SCHNEIDER

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K9/0019 ,  A61K39/39591 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/94

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

公开(公告)号：US20140234323A1

公开(公告)日：2014-08-21

申请号：US14268242

申请日：2014-05-02

Applicant: Innate Pharma

Inventor： KARINE CHEMIN ,  LAURENT GAUTHIER ,  YANNIS MOREL ,  CARINE PATUREL ,  AGNES TISSERANT

IPC: C07K16/30 ,  G01N33/574

CPC classification number: C07K16/30 ,  C07K16/2896 ,  G01N33/57415 ,  G01N33/57492

Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.

Abstract translation: 本发明涉及特异性结合存在于细胞表面上的TLR3细胞受体的抗体，抗体片段及其衍生物。 本发明还涉及产生这种抗体的杂交瘤; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体检测细胞表面上的TLR3水平的方法，以及在受试者中用于诊断或治疗目的的此类抗体和组合物的用途。